Document is current
Any future updates will be listed below
-
Authors
Agusti, Alvar https://orcid.org/0000-0003-3271-3788
Gibson, Peter G.
Heaney, Liam G.
Thomas, Mike https://orcid.org/0000-0001-5939-1155
-
Funding
Funding for this research was provided by:
GlaxoSmithKline (N/A, N/A, N/A)
GlaxoSmithKline Australia (N/A)
- License Information
-
More Information
Article History
Received: 12 February 2024
Accepted: 8 July 2024
First Online: 18 July 2024
Competing interests
: AA has research grants from AstraZeneca, GSK and Menarini; is a lector for AstraZeneca, Chiesi, Cipla, GSK, Menarini, Sanofi and Zambon; and is a member of scientific boards for AstraZeneca, Chiesi, GSK, Menarini and Sanofi. PGG has research grants from AstraZeneca and GSK; consulting lecturing and advisory board honoraria from AstraZeneca, Chiesi, GSK, Novartis and Sanofi; and is a respiratory physician at John Hunter Hospital, New South Wales, Australia. LGH has research grants from Aerocrine, Amgen, AstraZeneca, Genentech (Roche), GSK, MedImmune, Novartis and Vitalograph; consulting lecturing and advisory board honoraria from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Evelo Biosciences, GSK, Napp Pharmaceuticals, Novartis, Roche, Teva and Theravance; and is a clinical professor a Queens University and Belfast City Hospital, Belfast, UK. MT has consulting lecturing honoraria from GSK and is an Emeritus Professor of Primary Care Research at the University of Southampton, UK. All authors have no non-financial competing interests.
